Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Issues

Volume 19, Issue 4
15 February 2013
Issue Cover
All Issues
  • Cover Image

    Cover Image

    issue cover
    The image displays a human prostate cell line (PC-3) that has been stained with antibodies against the autophagy marker Light Chain 3 (LC3; green) after rapamycin treatment. During autophagy, LC3-I is converted to LC3-II through lipidation by a ubiquitin-like system involving Atg7 and Atg3 that allows for LC3 to become associated with autophagic vesicles, as shown by green punctea. Tumor cell nuclei are visualized by DAPI (blue). For details, see the article by Lamoureux and colleagues on page 833 of this issue.
  • PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265

Highlights

Highlights of This Issue
View articletitled, Highlights of This Issue
Open the PDF for in another window

CCR Translations

Predictive Biomarkers to Anti-VEGF Therapy: Progress toward an Elusive Goal
Rekha Gyanchandani; Seungwon Kim
View articletitled, Predictive Biomarkers to Anti-VEGF Therapy: Progress toward an Elusive Goal
Open the PDF for in another window

Molecular Pathways

Molecular Pathways: Multimodal Cancer-Killing Mechanisms Employed by Oncolytic Vesiculoviruses
Douglas J. Mahoney; David F. Stojdl
View articletitled, Molecular Pathways: Multimodal Cancer-Killing Mechanisms Employed by Oncolytic Vesiculoviruses
Open the PDF for in another window

Review

The Definition of Primary and Secondary Glioblastoma
Hiroko Ohgaki; Paul Kleihues
View articletitled, The Definition of Primary and Secondary Glioblastoma
Open the PDF for in another window

Human Cancer Biology

Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas
Mark L. McCleland; Adam S. Adler; Laura Deming; Ely Cosino; Leslie Lee; Elizabeth M. Blackwood; Margaret Solon; Janet Tao; Li Li; David Shames; Erica Jackson; William F. Forrest; Ron Firestein
View articletitled, Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas
Supplementary data
Open the PDF for in another window
Reciprocal Interactions between Tumor-Associated Macrophages and CD44-Positive Cancer Cells via Osteopontin/CD44 Promote Tumorigenicity in Colorectal Cancer
Guanhua Rao; Hongyi Wang; Baowei Li; Li Huang; Danfeng Xue; Xiaohui Wang; Haijing Jin; Jun Wang; Yushan Zhu; Youyong Lu; Lei Du; Quan Chen
View articletitled, Reciprocal Interactions between Tumor-Associated Macrophages and CD44-Positive Cancer Cells via Osteopontin/CD44 Promote Tumorigenicity in Colorectal Cancer
Supplementary data
Open the PDF for in another window
SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells
Michael S. Leibowitz; Raghvendra M. Srivastava; Pedro A. Andrade Filho; Ann Marie Egloff; Lin Wang; Raja R. Seethala; Soldano Ferrone; Robert L. Ferris
View articletitled, SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells
Supplementary data
Open the PDF for in another window
Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
Tarrik M. Zaid; Tsz-Lun Yeung; Melissa S. Thompson; Cecilia S. Leung; Tom Harding; Ngai-Na Co; Rosie S. Schmandt; Suet-Ying Kwan; Cristian Rodriguez-Aguay; Gabriel Lopez-Berestein; Anil K. Sood; Kwong-Kwok Wong; Michael J. Birrer; Samuel C. Mok
View articletitled, Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
Supplementary data
Open the PDF for in another window

Cancer Therapy: Preclinical

Influence of Human OATP1B1, OATP1B3, and OATP1A2 on the Pharmacokinetics of Methotrexate and Paclitaxel in Humanized Transgenic Mice
Evita van de Steeg; Anita van Esch; Els Wagenaar; Kathryn E. Kenworthy; Alfred H. Schinkel
View articletitled, Influence of Human OATP1B1, OATP1B3, and OATP1A2 on the Pharmacokinetics of Methotrexate and Paclitaxel in Humanized Transgenic Mice
Supplementary data
Open the PDF for in another window
Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363
Francois Lamoureux; Christian Thomas; Claire Crafter; Masafumi Kumano; Fan Zhang; Barry R. Davies; Martin E. Gleave; Amina Zoubeidi
View articletitled, Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363
Supplementary data
Open the PDF for in another window
Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells
Hirohito Yamaguchi; Jennifer L. Hsu; Chun-Te Chen; Ying-Nai Wang; Ming-Chuan Hsu; Shih-Shin Chang; Yi Du; How-Wen Ko; Roy Herbst; Mien-Chie Hung
View articletitled, Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells
Supplementary data
Open the PDF for in another window
Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts
Randall J. Kimple; Paul M. Harari; Alexandra D. Torres; Robert Z. Yang; Benjamin J. Soriano; Menggang Yu; Eric A. Armstrong; Grace C. Blitzer; Molly A. Smith; Laurel D. Lorenz; Denis Lee; David T. Yang; Timothy M. McCulloch; Gregory K. Hartig; Paul F. Lambert
View articletitled, Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts
Supplementary data
Open the PDF for in another window
Topotecan and Doxorubicin Combination to Treat Recurrent Ovarian Cancer: The Influence of Drug Exposure Time and Delivery Systems to Achieve Optimum Therapeutic Activity
Nilesh A. Patankar; Julia Pritchard; Mariska van Grinsven; Maryam Osooly; Marcel B. Bally
View articletitled, Topotecan and Doxorubicin Combination to Treat Recurrent Ovarian Cancer: The Influence of Drug Exposure Time and Delivery Systems to Achieve Optimum Therapeutic Activity
Supplementary data
Open the PDF for in another window

Imaging, Diagnosis, Prognosis

DNA Methylation as an Adjunct to Histopathology to Detect Prevalent, Inconspicuous Dysplasia and Early-Stage Neoplasia in Barrett's Esophagus
Muhammad A. Alvi; Xinxue Liu; Maria O'Donovan; Richard Newton; Lorenz Wernisch; Nicholas B. Shannon; Kareem Shariff; Massimiliano di Pietro; Jacques J.G.H.M. Bergman; Krish Ragunath; Rebecca C. Fitzgerald
View articletitled, DNA Methylation as an Adjunct to Histopathology to Detect Prevalent, Inconspicuous Dysplasia and Early-Stage Neoplasia in Barrett's Esophagus
Supplementary data
Open the PDF for in another window
The Immune Signature of CD8+CCR7+ T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC
Malgorzata Czystowska; William Gooding; Miroslaw J. Szczepanski; Andres Lopez-Abaitero; Robert L. Ferris; Jonas T. Johnson; Theresa L. Whiteside
View articletitled, The Immune Signature of CD8<sup>+</sup>CCR7<sup>+</sup> T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC
Supplementary data
Open the PDF for in another window

Cancer Therapy: Clinical

A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
David A. Reardon; Morris D. Groves; Patrick Y. Wen; Louis Nabors; Tom Mikkelsen; Steve Rosenfeld; Jeffrey Raizer; Jorge Barriuso; Roger E. McLendon; A. Benjamin Suttle; Bo Ma; C. Martin Curtis; Mohammed M. Dar; Johann de Bono
View articletitled, A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
Supplementary data
Open the PDF for in another window
First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies
Timothy A. Yap; Hendrik-Tobias Arkenau; D. Ross Camidge; Suzanne George; Natalie J. Serkova; Stephen J. Gwyther; Jennifer L. Spratlin; Rohit Lal; James Spicer; Nandita M. Desouza; Martin O. Leach; Jon Chick; Srinivasu Poondru; Ramesh Boinpally; Richard Gedrich; Katie Brock; Andrew Stephens; S. Gail Eckhardt; Stan B. Kaye; George Demetri; Michelle Scurr
View articletitled, First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies
Supplementary data
Open the PDF for in another window
First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma
Andrew X. Zhu; Philip J. Gold; Anthony B. El-Khoueiry; Thomas A. Abrams; Hideo Morikawa; Norihisa Ohishi; Toshihiko Ohtomo; Philip A. Philip
View articletitled, First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma
Open the PDF for in another window

Predictive Biomarkers and Personalized Medicine

Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Priti S. Hegde; Adrian M. Jubb; Dafeng Chen; Nicole F. Li; Y. Gloria Meng; Coen Bernaards; Rebecca Elliott; Stefan J. Scherer; Daniel S. Chen
View articletitled, Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Supplementary data
Open the PDF for in another window
Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
Reda Z. Mahfouz; Ania Jankowska; Quteba Ebrahem; Xiaorong Gu; Valeria Visconte; Ali Tabarroki; Pramod Terse; Joseph Covey; Kenneth Chan; Yonghua Ling; Kory J. Engelke; Mikkael A. Sekeres; Ramon Tiu; Jaroslaw Maciejewski; Tomas Radivoyevitch; Yogen Saunthararajah
View articletitled, Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
Supplementary data
Open the PDF for in another window

Letters to the Editor

Long-term Prospective Population PK Study in GIST Patients—Letter
Etienne Chatelut; Peggy Gandia; Verena Gotta; Nicolas Widmer
View articletitled, Long-term Prospective Population PK Study in GIST Patients—Letter
Open the PDF for in another window
Long-term Prospective Population PK Study in GIST Patients—Response
Ron H.J. Mathijssen; Peter de Bruijn; Karel Eechoute; Alex Sparreboom
View articletitled, Long-term Prospective Population PK Study in GIST Patients—Response
Open the PDF for in another window

Correction

Correction: Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
View articletitled, Correction: Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Open the PDF for in another window

Advertisement

Breaking
AbbVie Inks Deal for T-Cell Engager
GSK Buys Gastrointestinal-Focused Biopharma
Eli Lilly Snaps Up PI3Kα Inhibitor
View more recent articles
Latest News
South Asian Scholars Urge Action on Cancer Inequities
Greater Certainty of Survival Valued Over Speedier Drug Access
Keto Diet Key to Fueling CARs?
View more recent articles
Research Watch
The Zinc-Binding Cysteine Proteome Comprises Targetable Cancer Vulnerabilities
Engineered Focal Oncogene Amplifications Drive Transformation and Progression
Glycolysis Dictates Response to Fasting-Mimicking Diet in Breast Cancer
View more recent articles

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.

  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2025 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept